Alteration of PD-L1 (SP142) status after neoadjuvant chemotherapy and its clinical significance in triple-negative breast cancer
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
1 Online-Ressource.
- Language
-
Englisch
- Bibliographic citation
-
Alteration of PD-L1 (SP142) status after neoadjuvant chemotherapy and its clinical significance in triple-negative breast cancer ; day:16 ; month:5 ; year:2024 ; pages:1-11
Breast cancer research and treatment ; (16.5.2024), 1-11
- Creator
-
Woo, Ji Won
Han, Eun Kyung
Suh, Koung Jin
Kim, Se Hyun
Kim, Jee Hyun
Park, So Yeon
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s10549-024-07359-x
- URN
-
urn:nbn:de:101:1-2407252102001.034477473109
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:46 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Woo, Ji Won
- Han, Eun Kyung
- Suh, Koung Jin
- Kim, Se Hyun
- Kim, Jee Hyun
- Park, So Yeon
- SpringerLink (Online service)
Other Objects (12)
PD-L1 expression and CD274 gene alteration in triple-negative breast cancer: implication for prognostic biomarker
Clinical impact of PD-L1 expression in triple-negative breast cancer patients with residual tumor burden after neoadjuvant chemotherapy
Correction: Clinical impact of PD-L1 expression in triple-negative breast cancer patients with residual tumor burden after neoadjuvant chemotherapy
The risk of PD-L1 expression misclassification in triple-negative breast cancer
PD-L1 blockade TAM-dependently potentiates mild photothermal therapy against triple-negative breast cancer
Applicability of PD-L1 tests to tailor triple-negative breast cancer treatment in Brazil
Clinical and genomic assessment of PD-L1 SP142 expression in triple-negative breast cancer
Expression of PD-L1 in triple-negative breast cancer based on different immunohistochemical antibodies
Variation of PD-L1 expression in locally advanced cervical cancer following neoadjuvant chemotherapy
Simultaneous glutamine metabolism and PD-L1 inhibition to enhance suppression of triple-negative breast cancer
Diagnostic biopsy does not accurately reflect the PD-L1 expression in triple-negative breast cancer
Expression von VISTA beim neoadjuvant behandelten Mammakarzinom : Korrelation mit PD-L1 und dem Therapieansprechen
PD-L1 expression and CD274 gene alteration in triple-negative breast cancer: implication for prognostic biomarker
Clinical impact of PD-L1 expression in triple-negative breast cancer patients with residual tumor burden after neoadjuvant chemotherapy
Correction: Clinical impact of PD-L1 expression in triple-negative breast cancer patients with residual tumor burden after neoadjuvant chemotherapy
The risk of PD-L1 expression misclassification in triple-negative breast cancer
PD-L1 blockade TAM-dependently potentiates mild photothermal therapy against triple-negative breast cancer
Applicability of PD-L1 tests to tailor triple-negative breast cancer treatment in Brazil
Clinical and genomic assessment of PD-L1 SP142 expression in triple-negative breast cancer
Expression of PD-L1 in triple-negative breast cancer based on different immunohistochemical antibodies
Variation of PD-L1 expression in locally advanced cervical cancer following neoadjuvant chemotherapy
Simultaneous glutamine metabolism and PD-L1 inhibition to enhance suppression of triple-negative breast cancer
Diagnostic biopsy does not accurately reflect the PD-L1 expression in triple-negative breast cancer
Expression von VISTA beim neoadjuvant behandelten Mammakarzinom : Korrelation mit PD-L1 und dem Therapieansprechen
PD-L1 expression and CD274 gene alteration in triple-negative breast cancer: implication for prognostic biomarker
Clinical impact of PD-L1 expression in triple-negative breast cancer patients with residual tumor burden after neoadjuvant chemotherapy
Correction: Clinical impact of PD-L1 expression in triple-negative breast cancer patients with residual tumor burden after neoadjuvant chemotherapy
The risk of PD-L1 expression misclassification in triple-negative breast cancer
PD-L1 blockade TAM-dependently potentiates mild photothermal therapy against triple-negative breast cancer
Applicability of PD-L1 tests to tailor triple-negative breast cancer treatment in Brazil
Clinical and genomic assessment of PD-L1 SP142 expression in triple-negative breast cancer
Expression of PD-L1 in triple-negative breast cancer based on different immunohistochemical antibodies
Variation of PD-L1 expression in locally advanced cervical cancer following neoadjuvant chemotherapy
Simultaneous glutamine metabolism and PD-L1 inhibition to enhance suppression of triple-negative breast cancer
Diagnostic biopsy does not accurately reflect the PD-L1 expression in triple-negative breast cancer